PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study
Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody‐drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti‐PSMA monoclonal antibody conjugated to monomethy...
Saved in:
| Published in | The Prostate Vol. 80; no. 1; pp. 99 - 108 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.01.2020
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody‐drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti‐PSMA monoclonal antibody conjugated to monomethylauristatin E, which binds to PSMA‐positive cells and induces cytotoxicity. In a phase 1 study, PSMA ADC was well tolerated and demonstrated activity as measured by reductions in serum prostate‐specific antigen (PSA) and circulating tumor cells (CTCs). To further assess PSMA ADC, we conducted a phase 2 trial in metastatic castration‐resistant prostate cancer (mCRPC) subjects who progressed following abiraterone/enzalutamide (abi/enz) therapy.
Methods
A total of 119 (84 chemotherapy‐experienced and 35 chemotherapy‐naïve) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed.
Results
PSA declines ≥50% occurred in 14% of all treated (n = 113) and 21% of chemotherapy‐naïve subjects (n = 34). CTC declines ≥50% were seen in 78% of all treated (n = 77; number of subjects with ≥5 CTCs at baseline and a posttreatment result) and 89% of chemotherapy‐naïve subjects (n = 19); 47% of all treated and 53% of chemotherapy‐naïve subjects had a transition from ≥5 to less than 5 CTCs/7.5 mL blood at some point during the study. PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers. In the chemotherapy‐experienced group, the best overall radiologic response to PSMA ADC treatment was stable disease in 51 (60.7%) subjects; 5.7% of subjects in the chemotherapy‐naïve group had partial responses. The most common treatment‐related AEs ≥Common Terminology Criteria for AE (CTCAE) grade 3 were neutropenia, fatigue, electrolyte imbalance, anemia, and neuropathy. The most common serious AEs were dehydration, hyponatremia, febrile neutropenia, and constipation. Two subjects who received 2.5 mg/kg died of sepsis.
Conclusions
PSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment‐related AEs included neutropenia and neuropathy. |
|---|---|
| AbstractList | BackgroundProstate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody‐drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti‐PSMA monoclonal antibody conjugated to monomethylauristatin E, which binds to PSMA‐positive cells and induces cytotoxicity. In a phase 1 study, PSMA ADC was well tolerated and demonstrated activity as measured by reductions in serum prostate‐specific antigen (PSA) and circulating tumor cells (CTCs). To further assess PSMA ADC, we conducted a phase 2 trial in metastatic castration‐resistant prostate cancer (mCRPC) subjects who progressed following abiraterone/enzalutamide (abi/enz) therapy.MethodsA total of 119 (84 chemotherapy‐experienced and 35 chemotherapy‐naïve) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed.ResultsPSA declines ≥50% occurred in 14% of all treated (n = 113) and 21% of chemotherapy‐naïve subjects (n = 34). CTC declines ≥50% were seen in 78% of all treated (n = 77; number of subjects with ≥5 CTCs at baseline and a posttreatment result) and 89% of chemotherapy‐naïve subjects (n = 19); 47% of all treated and 53% of chemotherapy‐naïve subjects had a transition from ≥5 to less than 5 CTCs/7.5 mL blood at some point during the study. PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers. In the chemotherapy‐experienced group, the best overall radiologic response to PSMA ADC treatment was stable disease in 51 (60.7%) subjects; 5.7% of subjects in the chemotherapy‐naïve group had partial responses. The most common treatment‐related AEs ≥Common Terminology Criteria for AE (CTCAE) grade 3 were neutropenia, fatigue, electrolyte imbalance, anemia, and neuropathy. The most common serious AEs were dehydration, hyponatremia, febrile neutropenia, and constipation. Two subjects who received 2.5 mg/kg died of sepsis.ConclusionsPSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment‐related AEs included neutropenia and neuropathy. Prostate-specific membrane antigen (PSMA) is a well-established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody-drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti-PSMA monoclonal antibody conjugated to monomethylauristatin E, which binds to PSMA-positive cells and induces cytotoxicity. In a phase 1 study, PSMA ADC was well tolerated and demonstrated activity as measured by reductions in serum prostate-specific antigen (PSA) and circulating tumor cells (CTCs). To further assess PSMA ADC, we conducted a phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC) subjects who progressed following abiraterone/enzalutamide (abi/enz) therapy.BACKGROUNDProstate-specific membrane antigen (PSMA) is a well-established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody-drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti-PSMA monoclonal antibody conjugated to monomethylauristatin E, which binds to PSMA-positive cells and induces cytotoxicity. In a phase 1 study, PSMA ADC was well tolerated and demonstrated activity as measured by reductions in serum prostate-specific antigen (PSA) and circulating tumor cells (CTCs). To further assess PSMA ADC, we conducted a phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC) subjects who progressed following abiraterone/enzalutamide (abi/enz) therapy.A total of 119 (84 chemotherapy-experienced and 35 chemotherapy-naïve) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed.METHODSA total of 119 (84 chemotherapy-experienced and 35 chemotherapy-naïve) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed.PSA declines ≥50% occurred in 14% of all treated (n = 113) and 21% of chemotherapy-naïve subjects (n = 34). CTC declines ≥50% were seen in 78% of all treated (n = 77; number of subjects with ≥5 CTCs at baseline and a posttreatment result) and 89% of chemotherapy-naïve subjects (n = 19); 47% of all treated and 53% of chemotherapy-naïve subjects had a transition from ≥5 to less than 5 CTCs/7.5 mL blood at some point during the study. PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers. In the chemotherapy-experienced group, the best overall radiologic response to PSMA ADC treatment was stable disease in 51 (60.7%) subjects; 5.7% of subjects in the chemotherapy-naïve group had partial responses. The most common treatment-related AEs ≥Common Terminology Criteria for AE (CTCAE) grade 3 were neutropenia, fatigue, electrolyte imbalance, anemia, and neuropathy. The most common serious AEs were dehydration, hyponatremia, febrile neutropenia, and constipation. Two subjects who received 2.5 mg/kg died of sepsis.RESULTSPSA declines ≥50% occurred in 14% of all treated (n = 113) and 21% of chemotherapy-naïve subjects (n = 34). CTC declines ≥50% were seen in 78% of all treated (n = 77; number of subjects with ≥5 CTCs at baseline and a posttreatment result) and 89% of chemotherapy-naïve subjects (n = 19); 47% of all treated and 53% of chemotherapy-naïve subjects had a transition from ≥5 to less than 5 CTCs/7.5 mL blood at some point during the study. PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers. In the chemotherapy-experienced group, the best overall radiologic response to PSMA ADC treatment was stable disease in 51 (60.7%) subjects; 5.7% of subjects in the chemotherapy-naïve group had partial responses. The most common treatment-related AEs ≥Common Terminology Criteria for AE (CTCAE) grade 3 were neutropenia, fatigue, electrolyte imbalance, anemia, and neuropathy. The most common serious AEs were dehydration, hyponatremia, febrile neutropenia, and constipation. Two subjects who received 2.5 mg/kg died of sepsis.PSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment-related AEs included neutropenia and neuropathy.CONCLUSIONSPSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment-related AEs included neutropenia and neuropathy. Prostate-specific membrane antigen (PSMA) is a well-established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody-drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti-PSMA monoclonal antibody conjugated to monomethylauristatin E, which binds to PSMA-positive cells and induces cytotoxicity. In a phase 1 study, PSMA ADC was well tolerated and demonstrated activity as measured by reductions in serum prostate-specific antigen (PSA) and circulating tumor cells (CTCs). To further assess PSMA ADC, we conducted a phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC) subjects who progressed following abiraterone/enzalutamide (abi/enz) therapy. A total of 119 (84 chemotherapy-experienced and 35 chemotherapy-naïve) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed. PSA declines ≥50% occurred in 14% of all treated (n = 113) and 21% of chemotherapy-naïve subjects (n = 34). CTC declines ≥50% were seen in 78% of all treated (n = 77; number of subjects with ≥5 CTCs at baseline and a posttreatment result) and 89% of chemotherapy-naïve subjects (n = 19); 47% of all treated and 53% of chemotherapy-naïve subjects had a transition from ≥5 to less than 5 CTCs/7.5 mL blood at some point during the study. PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers. In the chemotherapy-experienced group, the best overall radiologic response to PSMA ADC treatment was stable disease in 51 (60.7%) subjects; 5.7% of subjects in the chemotherapy-naïve group had partial responses. The most common treatment-related AEs ≥Common Terminology Criteria for AE (CTCAE) grade 3 were neutropenia, fatigue, electrolyte imbalance, anemia, and neuropathy. The most common serious AEs were dehydration, hyponatremia, febrile neutropenia, and constipation. Two subjects who received 2.5 mg/kg died of sepsis. PSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment-related AEs included neutropenia and neuropathy. Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody‐drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti‐PSMA monoclonal antibody conjugated to monomethylauristatin E, which binds to PSMA‐positive cells and induces cytotoxicity. In a phase 1 study, PSMA ADC was well tolerated and demonstrated activity as measured by reductions in serum prostate‐specific antigen (PSA) and circulating tumor cells (CTCs). To further assess PSMA ADC, we conducted a phase 2 trial in metastatic castration‐resistant prostate cancer (mCRPC) subjects who progressed following abiraterone/enzalutamide (abi/enz) therapy. Methods A total of 119 (84 chemotherapy‐experienced and 35 chemotherapy‐naïve) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed. Results PSA declines ≥50% occurred in 14% of all treated (n = 113) and 21% of chemotherapy‐naïve subjects (n = 34). CTC declines ≥50% were seen in 78% of all treated (n = 77; number of subjects with ≥5 CTCs at baseline and a posttreatment result) and 89% of chemotherapy‐naïve subjects (n = 19); 47% of all treated and 53% of chemotherapy‐naïve subjects had a transition from ≥5 to less than 5 CTCs/7.5 mL blood at some point during the study. PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers. In the chemotherapy‐experienced group, the best overall radiologic response to PSMA ADC treatment was stable disease in 51 (60.7%) subjects; 5.7% of subjects in the chemotherapy‐naïve group had partial responses. The most common treatment‐related AEs ≥Common Terminology Criteria for AE (CTCAE) grade 3 were neutropenia, fatigue, electrolyte imbalance, anemia, and neuropathy. The most common serious AEs were dehydration, hyponatremia, febrile neutropenia, and constipation. Two subjects who received 2.5 mg/kg died of sepsis. Conclusions PSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment‐related AEs included neutropenia and neuropathy. |
| Author | Wadlow, Raymond Petrylak, Daniel P. Stambler, Nancy Sartor, A. Oliver Somer, Bradley Mega, Anthony E. Hussain, Arif Olson, William C. Vogelzang, Nicholas J. Smith, David C. Shore, Neal D. Gore, Ira Modiano, Manuel DiPippo, Vincent A. Israel, Robert J. Tagawa, Scott T. Fleming, Mark T. Appleman, Leonard J. Chatta, Kamal McClay, Edward F. Singh, Parminder |
| Author_xml | – sequence: 1 givenname: Daniel P. surname: Petrylak fullname: Petrylak, Daniel P. email: Daniel.Petrylak@yale.edu organization: Yale University – sequence: 2 givenname: Nicholas J. surname: Vogelzang fullname: Vogelzang, Nicholas J. organization: Comprehensive Cancer Centers of Nevada – sequence: 3 givenname: Kamal surname: Chatta fullname: Chatta, Kamal organization: Virginia Mason Medical Center – sequence: 4 givenname: Mark T. surname: Fleming fullname: Fleming, Mark T. organization: Virginia Oncology Associates – sequence: 5 givenname: David C. surname: Smith fullname: Smith, David C. organization: University of Michigan – sequence: 6 givenname: Leonard J. surname: Appleman fullname: Appleman, Leonard J. organization: University of Pittsburgh – sequence: 7 givenname: Arif surname: Hussain fullname: Hussain, Arif organization: University of Maryland – sequence: 8 givenname: Manuel surname: Modiano fullname: Modiano, Manuel organization: Arizona Clinical Research Center – sequence: 9 givenname: Parminder surname: Singh fullname: Singh, Parminder organization: Mayo Clinic – sequence: 10 givenname: Scott T. surname: Tagawa fullname: Tagawa, Scott T. organization: Weill Cornell Medical College – sequence: 11 givenname: Ira surname: Gore fullname: Gore, Ira organization: Alabama Oncology – sequence: 12 givenname: Edward F. surname: McClay fullname: McClay, Edward F. organization: California Cancer Associates for Research and Excellence – sequence: 13 givenname: Anthony E. surname: Mega fullname: Mega, Anthony E. organization: The Miriam Hospital – sequence: 14 givenname: A. Oliver orcidid: 0000-0002-8777-7343 surname: Sartor fullname: Sartor, A. Oliver organization: Tulane University – sequence: 15 givenname: Bradley surname: Somer fullname: Somer, Bradley organization: West Cancer Center and Research Institute – sequence: 16 givenname: Raymond surname: Wadlow fullname: Wadlow, Raymond organization: Virginia Cancer Specialists – sequence: 17 givenname: Neal D. surname: Shore fullname: Shore, Neal D. organization: Carolina Urologic Research Center – sequence: 18 givenname: William C. surname: Olson fullname: Olson, William C. organization: Progenics Pharmaceuticals, Inc – sequence: 19 givenname: Nancy surname: Stambler fullname: Stambler, Nancy organization: Progenics Pharmaceuticals, Inc – sequence: 20 givenname: Vincent A. orcidid: 0000-0002-5529-4195 surname: DiPippo fullname: DiPippo, Vincent A. organization: Progenics Pharmaceuticals, Inc – sequence: 21 givenname: Robert J. surname: Israel fullname: Israel, Robert J. organization: Progenics Pharmaceuticals, Inc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31742767$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1DAUhi1URKeFDQ-ALLFBldL6Mokn7EZDuUhFrSisI8c57rhy7GA7jKYrHoEX4yV4EpyZwqJCrHzs_zt3H6ED5x0g9JySU0oIOxuCj6eM14w9QjNKalEQMi8P0IwwQYo55eIQHcV4S0jGCXuCDjkVcyYqMUM_r64_LvHyzQr33vm0hiCHLTYODzIZcCnijUlrnFPcBIjRfAPcQ5IxZVlhlY2QLe9-ff-RdZPfXZroCYCsOwUBa2-t3xh3g2VrMg8hN4Cl6858wODupB2T7E0Hr_G51kZJtZ1UHKWGtKvGDzClsLIFi2OOZCFfZejxsJYRMMMxjd32KXqspY3w7P48Rl_enn9evS8uLt99WC0vCsVLwYoFqdh8wZRoS1UyrjuutWJSt0qxiirKaqBalRVwynVZyjmpuFjomgERkoiOH6NX-7i5068jxNT0JiqwVjrwY2wYp2VdLRYVy-jLB-itH4PL1WWKlbQWpKaZenFPjW0PXTME08uwbf4sKgMne0Dl2cYA-i9CSTP9gmYaerP7BRkmD2Bl0m5NeVvG_tuF7l02xsL2P8Gbq0-X13uf37V8zAg |
| CitedBy_id | crossref_primary_10_3390_cancers12123782 crossref_primary_10_3389_fonc_2021_722277 crossref_primary_10_3389_fonc_2021_740868 crossref_primary_10_3390_cancers16173098 crossref_primary_10_2147_OTT_S485869 crossref_primary_10_1097_CCO_0000000000000767 crossref_primary_10_37349_etat_2022_00082 crossref_primary_10_3390_ijms241411327 crossref_primary_10_1002_ddr_22261 crossref_primary_10_1111_prd_12445 crossref_primary_10_1007_s11912_024_01524_7 crossref_primary_10_3390_cancers13092244 crossref_primary_10_1080_14737140_2023_2208352 crossref_primary_10_3389_fonc_2021_711258 crossref_primary_10_1016_j_bioorg_2024_107803 crossref_primary_10_1016_j_euf_2021_02_006 crossref_primary_10_1038_s41598_021_86551_1 crossref_primary_10_1146_annurev_med_081522_031439 crossref_primary_10_1158_2767_9764_CRC_22_0491 crossref_primary_10_1007_s11523_022_00872_3 crossref_primary_10_1016_j_critrevonc_2023_104189 crossref_primary_10_3390_md20080494 crossref_primary_10_7759_cureus_34490 crossref_primary_10_2967_jnumed_122_264128 crossref_primary_10_1016_j_pharmthera_2021_107917 crossref_primary_10_3390_cells9061522 crossref_primary_10_1016_j_clgc_2022_07_009 crossref_primary_10_3390_ijms24021435 crossref_primary_10_3389_fphar_2024_1385598 crossref_primary_10_3389_fonc_2022_957892 crossref_primary_10_3390_ijms24108543 crossref_primary_10_1177_17588359231170474 crossref_primary_10_2174_1871520623666221031105432 crossref_primary_10_1016_j_tranon_2022_101438 crossref_primary_10_1038_s41419_024_06837_w crossref_primary_10_1038_s41698_022_00323_2 crossref_primary_10_15421_022136 crossref_primary_10_3892_or_2024_8854 crossref_primary_10_3390_ijms23031158 crossref_primary_10_3390_diseases12050087 crossref_primary_10_1016_j_eururo_2023_11_018 crossref_primary_10_1158_1535_7163_MCT_23_0927 crossref_primary_10_1038_s41392_022_01042_7 crossref_primary_10_3390_molecules26082228 crossref_primary_10_3390_ijms22115501 crossref_primary_10_1097_MOU_0000000000001115 crossref_primary_10_1007_s00345_024_05109_8 crossref_primary_10_1007_s00432_022_04515_y crossref_primary_10_1016_j_pharmthera_2021_108106 crossref_primary_10_1038_s41391_021_00394_5 crossref_primary_10_3390_cancers14174189 crossref_primary_10_1177_17588359211053898 |
| Cites_doi | 10.1182/blood-2017-03-772210 10.1002/pros.23124 10.1056/NEJMoa1209096 10.1002/pros.23765 10.1158/1078-0432.CCR-05-2107 10.1158/1078-0432.CCR-08-0872 10.1158/1078-0432.CCR-11-1425 10.1158/1078-0432.CCR-04-1402 10.1136/bmj.i4405 10.1016/j.adro.2017.12.008 10.2174/092986712799462612 10.3322/caac.21551 10.1080/19420862.2016.1156829 10.1155/2010/617421 10.1148/rg.2017170035 10.18632/oncoscience.389 10.1101/cshperspect.a030361 10.1056/NEJMoa1207506 10.1200/JCO.2018.36.6_suppl.272 10.1016/j.urolonc.2017.01.020 10.3322/caac.21492 10.1007/s40265-017-0705-5 10.1016/j.urolonc.2016.07.005 10.1093/annonc/mdw401 10.1002/pros.22910 10.1056/NEJMoa1315815 10.1001/jama.2017.7248 10.1158/1078-0432.CCR-13-3309 10.1056/NEJMoa041318 10.1158/0008-5472.CAN-08-0249 10.3390/cancers10100345 10.1002/pros.22916 10.1002/pros.23883 10.1093/annonc/mdv267 10.1200/JCO.2011.38.0410 10.1016/j.clgc.2018.07.013 |
| ContentType | Journal Article |
| Copyright | 2019 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2019 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TO 8FD FR3 H94 K9. P64 RC3 7X8 |
| DOI | 10.1002/pros.23922 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | Genetics Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1097-0045 |
| EndPage | 108 |
| ExternalDocumentID | 31742767 10_1002_pros_23922 PROS23922 |
| Genre | article Multicenter Study Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Progenics Pharmaceuticals, Inc |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 123 1L6 1OB 1OC 1ZS 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XV2 ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- 53G AANHP AAYXX ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AEYWJ AFFNX AGHNM AGQPQ AGYGG ASPBG AVWKF AZFZN CITATION EJD FEDTE HF~ HVGLF LW6 M6P PALCI RIWAO RJQFR SAMSI ZGI ZXP CGR CUY CVF ECM EIF NPM 7T5 7TO 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY FR3 H94 K9. P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c3572-8062482c7b5c523fd3ffc2afbcc261c129e1fc56e313f55a406378f92e07a07d3 |
| IEDL.DBID | DR2 |
| ISSN | 0270-4137 1097-0045 |
| IngestDate | Fri Jul 11 04:41:01 EDT 2025 Fri Jul 25 10:11:36 EDT 2025 Thu Apr 03 07:01:48 EDT 2025 Tue Jul 01 00:24:50 EDT 2025 Thu Apr 24 23:05:30 EDT 2025 Wed Jan 22 16:36:05 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | mCRPC antibody-drug conjugate prostate-specific membrane antigen |
| Language | English |
| License | 2019 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3572-8062482c7b5c523fd3ffc2afbcc261c129e1fc56e313f55a406378f92e07a07d3 |
| Notes | Mayo Clinic Arizona, 13400 E. Shea Blvd, Scottsdale, AZ 85259. Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591. Salix Pharmaceuticals, 400 Somerset Corporate Blvd, Bridgewater, NJ 08807. Present address ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-5529-4195 0000-0002-8777-7343 |
| PMID | 31742767 |
| PQID | 2325197091 |
| PQPubID | 1016443 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2315968862 proquest_journals_2325197091 pubmed_primary_31742767 crossref_primary_10_1002_pros_23922 crossref_citationtrail_10_1002_pros_23922 wiley_primary_10_1002_pros_23922_PROS23922 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 1, 2020 2020-01-00 20200101 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – month: 01 year: 2020 text: January 1, 2020 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | The Prostate |
| PublicationTitleAlternate | Prostate |
| PublicationYear | 2020 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2017; 317 2010; 2010 2017; 4 2006; 12 2015; 75 2019; 79 2013; 368 2016; 76 2008; 14 2012; 19 2012; 18 2014; 371 2012; 367 2012; 30 2016; 34 2018; 68 2014; 20 2004; 10 2015; 26 2018; 8 2004; 351 2018; 3 2018; 4 2017; 37 2017; 77 2019; 69 2016; 355 2008; 68 2017; 35S 2018; 10 2016; 27 2018; 16 2016; 8 2018; 36 2017; 129 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_4_1 Narayanan R (e_1_2_8_12_1) 2017; 4 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 Akaza H (e_1_2_8_5_1) 2018; 4 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_32_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_33_1 e_1_2_8_30_1 |
| References_xml | – volume: 69 start-page: 7 issue: 1 year: 2019 end-page: 34 article-title: Cancer statistics, 2019 publication-title: CA Cancer J Clin – volume: 12 start-page: 2591 year: 2006 end-page: 2596 article-title: Potent antitumor activity of an auristatin‐conjugated, fully human monoclonal antibody to prostate‐specific membrane antigen publication-title: Clin Cancer Res – volume: 4 year: 2018 article-title: Metastatic castration‐resistant prostate cancer previously treated with docetaxel‐based chemotherapy: treatment patterns from the PROXIMA prospective registry publication-title: J Glob Oncol – volume: 35S start-page: S1 year: 2017 end-page: S13 article-title: Navigating the evolving therapeutic landscape in advanced prostate cancer publication-title: Urol Oncol – volume: 367 start-page: 1187 issue: 13 year: 2012 end-page: 1197 article-title: Increased survival with enzalutamide in prostate cancer after chemotherapy publication-title: N Engl J Med – volume: 68 start-page: 394 year: 2018 end-page: 424 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 14 start-page: 6302 year: 2008 end-page: 6309 article-title: Circulating tumor cells predict survival benefit from treatment in metastatic castration‐resistant prostate cancer publication-title: Clin Cancer Res – volume: 27 start-page: 2124 year: 2016 end-page: 2130 article-title: Phase I study of safety and pharmacokinetics of the anti‐MUC16 antibody‐drug conjugate DMUC5754A in patients with platinum‐resistant ovarian cancer or unresectable pancreatic cancer publication-title: Ann Oncol – volume: 317 start-page: 2532 year: 2017 end-page: 2542 article-title: The diagnosis and treatment of prostate cancer: a review publication-title: JAMA – volume: 30 start-page: 2183 year: 2012 end-page: 2189 article-title: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma publication-title: J Clin Oncol – volume: 75 start-page: 242 year: 2015 end-page: 254 article-title: Synergistic co‐targeting of prostate‐specific membrane antigen and androgen receptor in prostate cancer publication-title: Prostate – volume: 10 start-page: 345 issue: 10 year: 2018 article-title: Castration‐resistant prostate cancer refractory to second‐generation androgen receptor axis‐targeted agents: opportunities and challenges publication-title: Cancers (Basel) – volume: 355 year: 2016 article-title: Advances in the management of castration resistant prostate cancer publication-title: BMJ – volume: 19 start-page: 1346 year: 2012 end-page: 1359 article-title: GCPII imaging and cancer publication-title: Curr Med Chem – volume: 368 start-page: 138 issue: 2 year: 2013 end-page: 148 article-title: Abiraterone in metastatic prostate cancer without previous chemotherapy publication-title: N Engl J Med – volume: 37 start-page: 1512 issue: 5 year: 2017 end-page: 1536 article-title: Clinical PET imaging in prostate cancer publication-title: Radiographics – volume: 36 start-page: 272 issue: Suppl year: 2018 article-title: PSMA heterogeneity analysis in patients with metastatic castrate‐resistant prostate cancer (mCRPC): Imaging versus CTCs publication-title: J Clin Oncol – volume: 129 start-page: 3256 year: 2017 end-page: 3261 article-title: Phase 1 multicenter trial of brentuximab vedotin for steroid‐refractory acute graft‐versus‐host disease publication-title: Blood – volume: 34 start-page: 530.e15 issue: 12 year: 2016 end-page: 530.e21 article-title: Phase 1/2 multiple ascending dose trial of the prostate‐specific membrane antigen‐targeted antibody drug conjugate MLN2704 in metastatic castration‐resistant prostate cancer publication-title: Urol Oncol – volume: 79 start-page: 1597 issue: 14 year: 2019 end-page: 1603 article-title: A pilot study of prostate‐specific membrane antigen (PSMA) dynamics inmenundergoing treatment for advanced prostate cancer publication-title: Prostate – volume: 18 start-page: 248 year: 2012 end-page: 255 article-title: A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30‐positive hematologic malignancies publication-title: Clin Cancer Res – volume: 79 start-page: 604 issue: 6 year: 2019 end-page: 613 article-title: Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer publication-title: Prostate – volume: 8 year: 2018 article-title: The epidemiology of prostate cancer publication-title: Cold Spring Harb Perspect Med – volume: 3 start-page: 170 year: 2018 end-page: 180 article-title: Factors influencing prostate cancer patterns of care: an analysis of treatment variation using the SEER database publication-title: Adv Radiat Oncol – volume: 26 start-page: 2044 year: 2015 end-page: 2056 article-title: Treatment of mCRPC in the AR‐axis‐targeted therapy‐resistant state publication-title: Ann Oncol – volume: 371 start-page: 1028 year: 2014 end-page: 1038 article-title: AR‐V7 and resistance to enzalutamide and abiraterone in prostate cancer publication-title: N Engl J Med – volume: 4 start-page: 175 year: 2017 end-page: 177 article-title: Destroying the androgen receptor (AR)‐potential strategy to treat advanced prostate cancer publication-title: Oncoscience – volume: 68 start-page: 4447 issue: 11 year: 2008 end-page: 4454 article-title: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration‐resistant tumor growth publication-title: Cancer Res – volume: 75 start-page: 303 issue: 3 year: 2015 end-page: 313 article-title: Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts publication-title: Prostate – volume: 351 start-page: 1513 issue: 15 year: 2004 end-page: 1520 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med – volume: 8 start-page: 659 year: 2016 end-page: 671 article-title: Effects of antibody, drug, and linker on the preclinical and clinical toxicities of antibody‐drug conjugates publication-title: Mabs – volume: 77 start-page: 435 year: 2017 end-page: 445 article-title: Brentuximab vedotin: a review in CD30‐positive Hodgkin lymphoma publication-title: Drugs – volume: 76 start-page: 325 issue: 3 year: 2016 end-page: 334 article-title: Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer publication-title: Prostate – volume: 2010 year: 2010 article-title: Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer publication-title: J Oncol – volume: 16 start-page: e1133 issue: 6 year: 2018 end-page: e1139 article-title: Circulating tumor cells as a biomarker of survival and response to radium‐223 therapy: experience in a cohort of patients with metastatic castration‐resistant prostate cancer publication-title: Clin Genitourin Cancer – volume: 20 start-page: 2846 issue: 11 year: 2014 end-page: 2850 article-title: Aggressive variants of castration‐resistant prostate cancer publication-title: Clin Cancer Res – volume: 10 start-page: 8147 year: 2004 end-page: 8151 article-title: Approval summary: docetaxel in combination with prednisone for the treatment of androgen‐independent hormone‐refractory prostate cancer publication-title: Clin Cancer Res – ident: e_1_2_8_31_1 doi: 10.1182/blood-2017-03-772210 – ident: e_1_2_8_19_1 doi: 10.1002/pros.23124 – ident: e_1_2_8_21_1 doi: 10.1056/NEJMoa1209096 – ident: e_1_2_8_20_1 doi: 10.1002/pros.23765 – ident: e_1_2_8_16_1 doi: 10.1158/1078-0432.CCR-05-2107 – ident: e_1_2_8_24_1 doi: 10.1158/1078-0432.CCR-08-0872 – ident: e_1_2_8_33_1 doi: 10.1158/1078-0432.CCR-11-1425 – ident: e_1_2_8_38_1 doi: 10.1158/1078-0432.CCR-04-1402 – ident: e_1_2_8_14_1 doi: 10.1136/bmj.i4405 – ident: e_1_2_8_6_1 doi: 10.1016/j.adro.2017.12.008 – ident: e_1_2_8_15_1 doi: 10.2174/092986712799462612 – ident: e_1_2_8_4_1 doi: 10.3322/caac.21551 – ident: e_1_2_8_32_1 doi: 10.1080/19420862.2016.1156829 – ident: e_1_2_8_25_1 doi: 10.1155/2010/617421 – ident: e_1_2_8_30_1 doi: 10.1148/rg.2017170035 – volume: 4 start-page: 175 year: 2017 ident: e_1_2_8_12_1 article-title: Destroying the androgen receptor (AR)‐potential strategy to treat advanced prostate cancer publication-title: Oncoscience doi: 10.18632/oncoscience.389 – ident: e_1_2_8_3_1 doi: 10.1101/cshperspect.a030361 – ident: e_1_2_8_22_1 doi: 10.1056/NEJMoa1207506 – ident: e_1_2_8_28_1 doi: 10.1200/JCO.2018.36.6_suppl.272 – ident: e_1_2_8_8_1 doi: 10.1016/j.urolonc.2017.01.020 – ident: e_1_2_8_2_1 doi: 10.3322/caac.21492 – ident: e_1_2_8_34_1 doi: 10.1007/s40265-017-0705-5 – ident: e_1_2_8_37_1 doi: 10.1016/j.urolonc.2016.07.005 – ident: e_1_2_8_36_1 doi: 10.1093/annonc/mdw401 – ident: e_1_2_8_17_1 doi: 10.1002/pros.22910 – ident: e_1_2_8_9_1 doi: 10.1056/NEJMoa1315815 – ident: e_1_2_8_7_1 doi: 10.1001/jama.2017.7248 – ident: e_1_2_8_29_1 doi: 10.1158/1078-0432.CCR-13-3309 – ident: e_1_2_8_13_1 doi: 10.1056/NEJMoa041318 – ident: e_1_2_8_23_1 doi: 10.1158/0008-5472.CAN-08-0249 – ident: e_1_2_8_11_1 doi: 10.3390/cancers10100345 – volume: 4 year: 2018 ident: e_1_2_8_5_1 article-title: Metastatic castration‐resistant prostate cancer previously treated with docetaxel‐based chemotherapy: treatment patterns from the PROXIMA prospective registry publication-title: J Glob Oncol – ident: e_1_2_8_18_1 doi: 10.1002/pros.22916 – ident: e_1_2_8_27_1 doi: 10.1002/pros.23883 – ident: e_1_2_8_10_1 doi: 10.1093/annonc/mdv267 – ident: e_1_2_8_35_1 doi: 10.1200/JCO.2011.38.0410 – ident: e_1_2_8_26_1 doi: 10.1016/j.clgc.2018.07.013 |
| SSID | ssj0010002 |
| Score | 2.5001316 |
| Snippet | Background
Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic... Prostate-specific membrane antigen (PSMA) is a well-established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate... BackgroundProstate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic... Prostate-specific membrane antigen (PSMA) is a well-established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 99 |
| SubjectTerms | Aged Aged, 80 and over Androstenes - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use antibody‐drug conjugate Antigens Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antitumor activity Biomarkers, Tumor - blood Castration Chemotherapy Constipation Cytotoxicity Dehydration Drug Resistance, Neoplasm Humans Hyponatremia Immunoglobulin G Immunotoxins - adverse effects Immunotoxins - therapeutic use Male mCRPC Metastases Metastasis Middle Aged Monoclonal antibodies Neuropathy Neutropenia Oncology Phenylthiohydantoin - administration & dosage Phenylthiohydantoin - analogs & derivatives Prostate cancer prostate‐specific membrane antigen Prostatic Neoplasms, Castration-Resistant - blood Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - drug therapy Sepsis Survival Rate Terminology Treatment Outcome Tumor cells |
| Title | PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpros.23922 https://www.ncbi.nlm.nih.gov/pubmed/31742767 https://www.proquest.com/docview/2325197091 https://www.proquest.com/docview/2315968862 |
| Volume | 80 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELaqHhAX3o-lBQ2CC0ibbLxZ20VcotKqQipULZV6QSvba4uIZFNtNkXtiZ_AH-NP8EuY8T6qAkKCWyLPyk52Hp_HM58Ze24Sboyxo9hk6ALHVhWxMs7EWmjcYKRWKBsKZN-JvePx25PsZI297nphGn6IPuFGlhH8NRm4NsvhJWkoOpjlgGN4JwdMxVqEiA577ijKW4cjBC6TGD217LlJ-fDy0avR6DeIeRWxhpCze5N97BbbVJp8HqxqM7AXv_A4_u-vucVutFgUJo3y3GZrrrzDru23p-132feDo_0JTN5sA-pq26l1DtMSWjLWJVAWF0KJF1XTnjmYu1pTj9LUgtUdJe-Pr99wnIBqWZN0aGLCcdS3Cjwq4uILBlDQhs78XbUoHeiyGC4qcOWFRtPQ82nhXsEO0V1oe06jsNTe1WE1dAEYToHq7GZAqY-Zw6-6msPpJ4zRwCFw6N5jx7s7H7b34vb6h9immUQ_nQg-VtxKk1ncLvsi9d5y7Y21uO2zCFTcyNtMuHSU-izTCE1SqfwWd4nUiSzS-2y9xCU_ZJAZVTglCmW20EmNhBKpR1yMeMXxQqg0Yi86Nchty41OV3TM8obVmef05-Th_UTsWS972jCC_FFqs9OmvPUKNBL6hBGiRexpP4z2TIc0unSLFckgwBQKN5oRe9BoYT8NYr0xl0JG7GXQpb_Mnx8cvj8Knx79i_AGu84poRByTJtsva5W7jGirto8Cdb1E467MFA |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2hIgEvUG7FUGAQvIDkxFnH6y1vUS8K0JSqF6lv1u56V0QkTuU4oPapn8CP8RN8CTNrx1UBIcFbop1onWQuZ2dnzjD2Skdca216oU7QBfaNzEOprQ6VUHjAiI2QxhfI7onhcf_9SXLS1OZQL0zND9Em3MgyvL8mA6eEdPeSNRQ9zLzDMb6jB75OI72JOn_roGWPosy1v0TgaRSir05bdlLevfzs1Xj0G8i8ill90Nm5U09WnXuuQqo1-dxZVLpjzn9hcvzv77PKbjdwFAa1_txl12xxj90YNRfu99n3_cPRAAZbm4Dq2jRrncG4gIaPdQ6UyAVf5UUFtV8sTG2lqE1pbMCoJSvvj4tvuE5YtahI2vcx4TqqXAkOdXH2FWMoKE3X_racFRZUkXdnJdjiXKF1qOk4t29hmxgvlDmjVZgrZyv_NDQDDLdAjbYToOzHxOJbVU7h9BOGaeDgaXQfsOOd7aPNYdhMgAhNnKToqiPB-5KbVCcGT8wuj50zXDltDJ78DGIV23MmETbuxS5JFKKTOJVug9soVVGaxw_ZSoGP_IhBomVupcil3kA_1RNSxA6hMUIWy3Mh44C9XupBZhp6dJrSMclqYmee0Y-T-f8nYC9b2dOaFOSPUutLdcoax0ArvlUYUVrAXrTLaNJ0T6MKO1uQDGJMIfGsGbC1Wg3bbRDu9Xkq0oC98cr0l_2z_YOPh_7V438Rfs5uDo9Gu9nuu70PT9gtTvkFn3JaZytVubBPEYRV-pk3tZ9ccTRs |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLamIU28cL8EBhwELyClTZ3GcREv1bpqXDaqjUl7QZHt2KKiTas2BW1P_AT-GH-CX8I5TpppgJDgrdU5kd3mXD4f-3xm7KmOuNbadEKdYAjsGpmHUlsdKqFwgREbIY0_IHsg9o67r0-Skw32ct0LU_FDNAU38gwfr8nB57lrn5OGYoBZtjimdwzAl7oi6tHFDYPDhjyKCtd-D4GnUYihOm3ISXn7_NmL6eg3jHkRsvqcM7zKPqxnWx01-dRalbplzn4hcvzfn3ONXanBKPQr67nONmxxg23t19vtN9n30dF-H_qDHUBjrVu1TmFcQM3GugQq44I_40XHaT9bmNpSUZPS2IBRa07eH1-_oZyQalGStu9iQjka3AIcWuLsC2ZQUJo2_e1iVlhQRd6eLcAWZwp9Q03HuX0Bu8R3ocwpSWGpnC39bOgGMBwC7dlOgGofE4tf1WIK84-YpIGDJ9G9xY6Hu-939sL6_ofQxEmKgToSvCu5SXVicL3s8tg5w5XTxuC6zyBSsR1nEmHjTuySRCE2iVPpetxGqYrSPL7NNguc8l0GiZa5lSKXuodRqiOkiB0CYwQsludCxgF7tjaDzNTk6HRHxySraJ15Rn9O5t9PwJ40uvOKEuSPWttra8rqsEAS3yiMGC1gjxsxOjTt0qjCzlakgwhTSFxpBuxOZYXNMAj2ujwVacCee1v6y_jZ6PDdkf9071-UH7Gt0WCYvX118OY-u8ypuODrTdtss1ys7ANEYKV-6B3tJ62uMxs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PSMA+ADC+monotherapy+in+patients+with+progressive+metastatic+castration%E2%80%90resistant+prostate+cancer+following+abiraterone+and%2For+enzalutamide%3A+Efficacy+and+safety+in+open%E2%80%90label+single%E2%80%90arm+phase+2+study&rft.jtitle=The+Prostate&rft.au=Petrylak%2C+Daniel+P&rft.au=Vogelzang%2C+Nicholas+J&rft.au=Chatta%2C+Kamal&rft.au=Fleming%2C+Mark+T&rft.date=2020-01-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0270-4137&rft.eissn=1097-0045&rft.volume=80&rft.issue=1&rft.spage=99&rft.epage=108&rft_id=info:doi/10.1002%2Fpros.23922&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-4137&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-4137&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-4137&client=summon |